glp-1 drugs depression Most Medications Correlated with a Lower Likelihood of Anxiety and Diagnoses GLP-1 Drugs Linked to Higher

Monthly Monitoring Active Therapy 3

Conclusion Beyond their established role as potent antihyperglycemic agents, GLP-1RAs show potential for treating neurodegenerative diseases with disease-modifying effects

Artificial intelligence was used solely for language refinement, grammar correction, improving clarity, formatting, and enhancing academic style

Gastrointestinal and Gallbladder Effects Gastrointestinal symptoms are usually dose-related and may be mitigated by slower titration and taking smaller, lower-fat meals during the first weeks

Elderly patients and other special populations Older adults ( 65 years) with MASLD may experience greater gastrointestinal intolerance and dehydration risk

As weight loss drugs, semaglutide was approved as Wegovy in 2021 and tirzepatide was approved as Zepbound in 2023